Skip to main content

Table 4 Correlation between clinicopathological factors and CAF PD-L1 expression (E1L3N Assay)

From: Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

Factors

PD-L1-positive (n = 25)

PD-L1-negative (n = 36)

p-value

Age (years old; median ± SD)

 

68 ± 11

64 ± 17

0.268

Menopausal status

 premenopausal

1

8

0.067

 postmenopausal

24

27

 

 unknown

0

1

 

Tumour size (mm)

  ≤ 20

11

20

0.440

  > 20

14

16

 

Pathological stage

 I + II

21

32

0.706

 III

4

4

 

Lymph node status

 positive

6

8

0.534

 negative

18

15

 

 not tested

1

13

 

Lymphatic invasion

 positive

22

30

0.725

 negative

3

6

 

Venous invasion

 positive

15

22

1.000

 negative

10

14

 

Nottingham histlogical grade

 1 + 2

11

18

0.795

 3

14

18

 

Ki-67 labeling index (LI)

 high

13

15

0.792

 low

12

17

 

 not tested

0

4

 

Stromal TILs

 LPBC

12

7

0.025

 non-LPBC

13

29

 

PD-L1 on stromal TILs (E1L3N)

 positive

12

3

< 0.001

 negative

13

32

 

 not tested

0

1

 

Adjuvant chemotherapy

 performed

12

22

0.784

 not performed

10

14

 

 undetermined

3

0

 
  1. LPBC lymphocyte predominant breast cancer